Key result
Combined angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade was not superior to either treatment separately for improving endothelial function in hypertension.
Why the study?
Does single or combined pharmacologic inhibition of the renin-angiotensin-aldosterone system improve endothelial function and blood pressure in hypertensive patients?
RCT (n=88)
Does single or combined pharmacologic inhibition of the renin-angiotensin-aldosterone system improve endothelial function and blood pressure in hypertensive patients?
Antihypertensive therapy improves endothelial function in hypertensive patients, but combining an ACE inhibitor and an ARB offers no additional benefit over monotherapy.
Dual ACEI/ARB offers no endothelial advantage over monotherapy; leaves open effects on cardiovascular outcomes.
It is unclear whether single and combined pharmacologic inhibition of the renin-angiotensin-aldosterone system have similar effects on endothelial function and blood pressure (BP). The authors evaluated 63 hypertensive patients divided into 4 groups (hydrochlorothiazide 25 mg/d; irbesartan [IRBE] 150 mg/d; quinapril [QUIN] 20 mg/d; or IRBE 150 mg/d + QUIN 20 mg/d) and 25 healthy normotensive subjects (normal) followed for 12 weeks. Endothelium-dependent dysfunction measured as flow-mediated dilation at Weeks 0 and 12 were: normal, 11.5%+/-2.4% vs 13.5%+/-2.0%; hydrochlorothiazide, 7.3%+/-2.0% vs 12.8%+/-3.1%; QUIN, 7.2%+/-2.8% vs 13.2%+/-2.1%; IRBE, 7.1%+/-2.8% vs 13.0%+/-2.9%; and IRBE + QUIN, 7.5%+/-1.9% vs 12.8%+/-3.0%. Nitroglycerin-mediated responses were: normal, 26.0%+/-1.9% vs 24.0%+/-2.5%; hydrochlorothiazide, 17.0%+/-2.2% vs 18.3%+/-2.6%; QUIN, 17.8%+/-3.2% vs 23.4%+/-3.0%; IRBE, 16.8%+/-3.6% vs 24.7%+/-2.0%; and IRBE + QUIN, 17.3%+/-3.0% vs 25.1%+/-2.5%. Antihypertensive therapy restored BP to normal and improved the endothelium-dependent and -independent dysfunction after renin-angiotensin-aldosterone system blockade. In a further finding, the combined effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade was not superior to the action of either of these treatments separately.
No takes yet. Share an insight, caveat, or question.
Souza‐Barbosa et al. (2006) conducted an RCT in Hypertension (n=88). Irbesartan, quinapril, their combination, or hydrochlorothiazide vs. Healthy normotensive subjects was evaluated on Endothelium-dependent dysfunction measured as flow-mediated dilation. Combined angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade was not superior to either treatment separately for improving endothelial function in hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: